Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (551-560 of 755) with videos related to

Pageof 76
Sort By:
Annals of the Rheumatic Diseases|July 10, 2012
Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensusSusan J Bartlett, Sarah Hewlett, Clifton O Bingham, et al.
Biomedicines|August 29, 2024
The Potential Role of Butyrate in the Pathogenesis and Treatment of Autoimmune Rheumatic DiseasesCarmela Coccia, Francesco Bonomi, Anna Lo Cricchio, et al.
Arthritis Research & Therapy|August 15, 2021
The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to casesYukai Wang, Shaoqi Chen, Shaoyu Zheng, et al.
The Journal of Rheumatology|May 17, 2012
Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trialDésirée van der Heijde, Edward C Keystone, Jeffrey R Curtis, et al.
Clinical Rheumatology|November 24, 2020
Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SSc cohortsYossra Suliman, Suzanne Kafaja, Sunny J Oh, et al.
Annals of the Rheumatic Diseases|October 14, 2006
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006D E Furst, F C Breedveld, J R Kalden, et al.
Arthritis and Rheumatism|September 12, 2013
Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertensionDinesh Khanna, Heather Gladue, Richard Channick, et al.
Clinical and Experimental Rheumatology|July 29, 2021
A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationaleRobert Spiera, Dinesh Khanna, Masataka Kuwana, et al.
Arthritis and Rheumatism|June 16, 2001
A randomized, controlled trial of methotrexate versus placebo in early diffuse sclerodermaJ E Pope, N Bellamy, J R Seibold, et al.
ACR Open Rheumatology|February 2, 2023
Qualitative Interviews to Assess the Content Validity and Usability of the Electronic Raynaud Diary in Patients with Systemic SclerosisRobyn T Domsic, Robin Pokrzywinski, Larissa Stassek, et al.
Pageof 76

Showing results (551-560 of 755) with videos related to

Sort By:
Pageof 76
Annals of the Rheumatic Diseases|July 10, 2012
Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensusSusan J Bartlett, Sarah Hewlett, Clifton O Bingham, et al.
Biomedicines|August 29, 2024
The Potential Role of Butyrate in the Pathogenesis and Treatment of Autoimmune Rheumatic DiseasesCarmela Coccia, Francesco Bonomi, Anna Lo Cricchio, et al.
Arthritis Research & Therapy|August 15, 2021
The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to casesYukai Wang, Shaoqi Chen, Shaoyu Zheng, et al.
The Journal of Rheumatology|May 17, 2012
Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trialDésirée van der Heijde, Edward C Keystone, Jeffrey R Curtis, et al.
Clinical Rheumatology|November 24, 2020
Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SSc cohortsYossra Suliman, Suzanne Kafaja, Sunny J Oh, et al.
Annals of the Rheumatic Diseases|October 14, 2006
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006D E Furst, F C Breedveld, J R Kalden, et al.
Arthritis and Rheumatism|September 12, 2013
Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertensionDinesh Khanna, Heather Gladue, Richard Channick, et al.
Clinical and Experimental Rheumatology|July 29, 2021
A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationaleRobert Spiera, Dinesh Khanna, Masataka Kuwana, et al.
Arthritis and Rheumatism|June 16, 2001
A randomized, controlled trial of methotrexate versus placebo in early diffuse sclerodermaJ E Pope, N Bellamy, J R Seibold, et al.
ACR Open Rheumatology|February 2, 2023
Qualitative Interviews to Assess the Content Validity and Usability of the Electronic Raynaud Diary in Patients with Systemic SclerosisRobyn T Domsic, Robin Pokrzywinski, Larissa Stassek, et al.
Pageof 76